Plenary Session 1: Lupus in 2017: from molecular targets to new therapies

1 STEM CELLS AND THE TREATMENT OF SLE

L Sun, Nanjing, China

10.1136/lupus-2017-000215.1

Systemic lupus erythematosus (SLE) is a heterogeneous chronic multisystemic autoimmune inflammatory disorder. Autologous hematopoietic stem cell transplantation (HSCT) represents the first application of stem cell regenerative medicine in the treatment of drug-resistant SLE. The 5 year follow-up data showed that the overall survival was 84%, the probability of disease-free survival was 50% and treatment-related mortality was 4%. The European Group for Blood and Marrow Transplantation (EBMT) data showed that the 5 year overall survival was $81\% \pm 8\%$ and disease-free survival was $29\% \pm 9\%$, with a non-relapse mortality of $15\% \pm 7\%$, suggesting a satisfactory clinical efficacy of autologous HSCT for lupus patients. However, The biggest challenge for HSCT is the high rate of disease relapse, as well as the serious side effects of the conditioning therapy. Mesenchymal stem cells (MSCs) are widely studied as an alternative cell source for their ability to differentiate into multiple mesenchymal lineages, as well as endoderm and neuroectoderm lineages. We have shown that bone marrow derived MSCs from SLE patients are defective structurally and functionally. Then from March 2007, we started to use allogeneic bone marrow and umbilical cord derived MSCs transplantation (MSCT) for refractory SLE patients, especially for those with drug resistant lupus nephritis. Allogeneic MSCs were administered intravenously (one million cells per kilogram of bodyweight). The clinical manifestations and laboratory parameters were compared pre- and post-MSCT. During 4 years' follow up, complete remission was 28% at 1 year (23/83), 31% at 2 years (12/39), 42% at 3 years (5/12) and 50% at 4 years (3/6). Rates of relapse were 12% (10/83) at 1 year, 18% (7/39) at 2 years, 17% (2/12) at 3 years and 17% (1/6) at 4 years. Disease activity declined shown by significant changes in SLEDAI score, proteinuria, renal function, and levels of serum autoimmune antibodies, albumin and complement C3. Furthermore, we observed a long-term tissue repair effect by MSCs transplantation in our patients. Importantly, doses of corticosteroid and immunosuppressant were tapered or discontinued after MSCT. Taken together, allogeneic MSCT exerts a profound therapeutic effect in patients with severe and refractory SLE.

2 SHARED AND ENDORGAN SPECIFIC TRANSCRIPTIONAL NETWORKS IN SKIN VERSUS KIDNEY BIOPSIES IN SYSTEMIC LUPUS

¹CC Berthier*, ¹J Stannard, ¹EM Myers, ¹R Namas, ¹L Lowe, ¹T Reed, ²A Davidson, ¹M Kretzler, ¹JM Kahlenberg. ¹University of Michigan, Internal Medicine, Ann Arbor, USA; ²Feinstein Institute, Centre for Autoimmunity and Musculoskeletal Diseases, Manhasset- NY, USA

10.1136/lupus-2017-000215.2

Background and aims Skin rash can often herald the onset of a systemic disease flare in systemic lupus. The subtype of skin lesion may confer a differential risk of renal involvement. We

hypothesised that renal flares may exhibit crosstalk between skin and kidneys and that similar molecular mechanisms may underlie skin and renal disease.

Methods We used systems biology approaches to integrate the regulatory events occurring in subacute cutaneous lupus erythematosus (sCLE, n=43) and discoid lupus erythematosus (DLE, n=47) and compared with those in the ERCB lupus nephritis (LN) class II+IV cohort (n=22).

Results Shared transcriptional networks in SLE skin lesions versus LN kidney biopsies reflect similar pathway regulation (p-value<0.05) including complement, B-cells, dendritic cells (DCs), IL4, IL8, and inflammasome signalling pathways.

IL-12 signalling and production in macrophages, IL-3, IL-15 signalling pathways were regulated only in LN glomeruli and sCLE rashes, while there were metabolic pathways unique to DLE.

CCL21 mRNA expression was specifically up-regulated in sCLE and LN tubulointerstitium and correlated with eGFR, which suggests it may play a role in cutaneous and renal lupus pathogenesis.

Conclusions sCLE, which is associated with a higher risk of systemic disease involvement compared with DLE, shares overlapping gene regulation with lupus nephritis. Dendritic cell pathways and associated upregulation of the CCR7 ligand CCL21, that is involved in recruitment of immune effector cells, may serve as a marker for sCLE patients at risk for LN. These data thus identify potentially important molecular targets for novel therapies in cutaneous and renal lupus.

3 CONFIRMATION OF 5 NOVEL SUSCEPTIBILITY LOCI FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND INTEGRATED NETWORK ANALYSIS OF 82 SLE SUSCEPTIBILITY LOCI

¹S Nath*, ²W Yang, ³XJ Zhou, ¹C Sun, ⁴Y Okada, ⁵SC Bae, ⁶N Shen, ¹J Molineros. ¹Oklahoma Medical Research Foundation, Arthritis and Clinical Immunology, Oklahoma City, USA; ²The University of Hong Kong, Department of Paediatrics and Adolescent Medicine, Hong Kong, China; ³Peking University First Hospital- Peking University Institute of Nephrology, Renal Division, Beijing, China; ⁴Osaka University Graduate School of Medicine, Department of Statistical Genetics, Osaka, Japan; ⁵Hanyang University Hospital for Rheumatic Diseases, Department of Rheumatology, Seoul, Republic of Korea; ⁶Renji Hospital- Shanghai Institutes for Biological Sciences, Rheumatology, Shanghai, China

10.1136/lupus-2017-000215.3

Background and aims We recently identified ten novel SLE susceptibility loci in Asian populations and uncovered several additional suggestive loci requiring further validation. This study aimed to replicate five of these suggestive loci followed by meta-analysis, and perform a series of bioinformatic analyses on all 82 reported SLE loci to identify shared regulatory signatures.

Methods We investigated five loci in a Han Chinese cohort, and performed meta-analysis together with 11 656 cases and 23 968 controls from previously reported Asian and European populations. Epigenomic analysis was performed using ENCODE and GETEx data.

Results All five loci passed genome-wide significance: MYNN (rs10936599, Pmeta=1.92×10⁻¹³), ATG16L2 (rs11235604, Pmeta=8.87×10⁻¹²), CCL22 (rs223881, Pmeta=5.87×10⁻¹⁶), ANKS1A (rs2762340, Pmeta=4.93×10⁻¹⁵) and RNASEH2C (rs1308020, Pmeta=2.96×10⁻¹⁹) and co-located with annotated gene regulatory elements. The novel SLE loci share genetic signatures with other reported SLE loci, including